CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 23 enrolled
Drug / intervention
Cyanocobalamin +1 moredrug
Likely dose
Cyanocobalamin 1000 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04387201
NCT04387201Phase 4Completed
CompareCT.gov

GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response

The University of Texas Health Science Center, Houston·interventional·Posted May 13, 2020·Updated Dec 5, 2024

In Brief

A Phase 4 clinical trial evaluating Cyanocobalamin and Dulaglutide for Glucose Intolerance and 3 related conditions. Completed, enrolled 23 participants across 1 site.

Detailed Summary

This project investigates the anti-obesity mechanisms of glucagon-like peptide-1 (GLP-1) analogs, which are used in the treatment of human obesity and diabetes mellitus. The investigators will test if GLP-1 induces secretion of interleukin-6 (IL-6), a cytokine that may collaborate with GLP-1 analogs to induce the formation of brown fat, which has anti-diabetic properties. The results will guide future obesity and diabetes mellitus therapies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlucose Intolerance, Overweight and Obesity, Drug Effect, Adiposity
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedMay 13, 2020
Enrollment StartMay 15, 2020
Primary CompletionOct 6, 2023
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 6.1 years ago

Interventions

Cyanocobalamindrug

Cyanocobalamin (vitamin B12) 1000 mcg subcutaneous weekly for 6 weeks.

Dulaglutidedrug

Dulaglutide 0.75 mg subcutaneous weekly for 2 weeks, followed by 1.5 mg subcutaneous weekly for 4 weeks